Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Conference call to be held today, 25 April 2019, 3:00pm CET/2:00pm BST
Preparations for Upcoming Clinical Data in the MERECA and GIST Studies and First Patient Treated in the ILIAD Study
Assertio Therapeutics, Inc. announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of markets.
The project company Belina is running an innovative project in early phase and is developing a product for treatment of breast cancer.
Pharnext SA announced its financial results for the fiscal year ended December 31st, 2018.
MDxHealth SA, a commercial-stage innovative molecular diagnostics company, provided a business update for the first quarter ended March 31, 2019.
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.
Eur 140 m bridge loan was drawn to secure evotec’s value chain expansion by successful acquisition of aptuit in august 2017
312 shareholders attended, representing 60% of the issued share capital